Mayank Mamtani

Novavax, Inc. (NASDAQ: NVAX), which last month landed CEPI funding for its coronavirus vaccine program, announced Tuesday the  initiation of human studies of its vaccine candidate, NVX-CoV2373. The Novavax Analysts Cantor Fitzgerald analyst Charles Duncan maintained an...

Novavax, Inc. (NASDAQ: NVAX) announced Monday after the close an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations alongside forecast-beating first-quarter results. The Novavax Analysts H.C. Wainwright analyst Vernon Bernardino reiterated a Buy...

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), which plummeted 60% to $3.50 Thursday in reaction to a negative clinical readout, were rebounding Friday. The Spectrum Pharma Analyst B Riley FBR analyst Mayank Mamtani maintained a Buy rating on Spectrum and lowered the price target from $...